<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE nitf PUBLIC "-//IPTC//NITF DTD 3.0//EN" "nitf-3-0.dtd"><nitf baselang="EN-US"><head><meta content="CITE" name="_lnbillview"/><meta content="00001" name="_lnminrev"/><meta content="May 31, 2017" name="_eoptdate"/><meta content="10:43:27 EDT" name="_eopttime"/><meta content="DOCUMENT_TOKEN_PLACEHOLDER" name="documentToken"/><docdata><doc-id id-string="5NNS-RTV1-JC11-13D3" regsrc="lexisnexis.com"/><date.issue norm="20170530T000000Z"/>2017-05-30</docdata><pubdata unit-of-measure="word" item-length="1161" name=" Targeted News Service"/></head><body><body.head><hedline><hl1>Radboud University Medical Center, the Instituto de Medicina Molecular, and PATH's <em class="1" style="hit">Malaria</em> Vaccine Initiative Will Collaborate on First-in-Human Study of a Novel <em class="2" style="hit">Malaria</em> Vaccine Approach</hl1></hedline><byline>Targeted News Service</byline></body.head><body.content/></body></nitf>